A clinical trial has been established to study whether TIMP-2 and IGFBP7 could identify patients with COVID-19 at risk of developing AKI early (NCT04393428), and the findings of this investigation will be made public in the future. This evidence concerns the gene IGFBP7 and acute kidney injury.